Vir Biotechnology (NASDAQ: VIR) revenue
Vir Biotechnology reported revenue of $68.6m for fiscal 2025, 7.6% less than in fiscal 2024 ($74.2m). Since fiscal 2018 its revenue has grown by 542.6%, an average growth of 30.4% a year.
Vir Biotechnology's revenue has fallen for 3 years in a row, and its best year of the last 8 was fiscal 2022. The biggest drop was in fiscal 2023, −94.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $68.6m | −7.6% | −$479.3m | −699.2% |
| 2024 | $74.2m | −13.9% | −$587.2m | −791.3% |
| 2023 | $86.2m | −94.7% | −$684.3m | −794.0% |
| 2022 | $1,616m | +47.5% | $833.1m | 51.6% |
| 2021 | $1,095m | +1,334.4% | $420.8m | 38.4% |
| 2020 | $76.4m | +843.9% | −$297.0m | −388.9% |
| 2019 | $8.1m | −24.2% | −$178.0m | −2,199.7% |
| 2018 | $10.7m | — | −$118.7m | −1,112.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Vir Biotechnology revenue compared with its sector
By revenue for its latest fiscal year, Vir Biotechnology ranks 315th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Vir Biotechnology, −7.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 313th | Black Diamond Therapeutics | $70.0m | — |
| 314th | Personalis | $69.6m | −17.7% |
| 315th | Vir Biotechnology | $68.6m | −7.6% |
| 316th | Intellia Therapeutics | $67.7m | 16.9% |
| 317th | Kura Oncology | $67.5m | 25.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Vir Biotechnology
- How much revenue did Vir Biotechnology make in fiscal 2025?
- Vir Biotechnology reported revenue of $68.6m for fiscal 2025, compared with $74.2m in fiscal 2024.
- How much has the revenue of Vir Biotechnology grown?
- Between fiscal 2018 and fiscal 2025 it went from $10.7m to $68.6m: 542.6% more, an average growth of 30.4% a year.
- What was the best year for revenue at Vir Biotechnology?
- Of its last 8 fiscal years, fiscal 2022, with $1,616m.
- Where does Vir Biotechnology rank in its sector by revenue?
- It ranks 315th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Vir Biotechnology come from?
- From the annual report (Form 10-K) that Vir Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Vir Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Vir Biotechnology: the Vir Biotechnology page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.